With 0.17 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.28 million shares. During the session, the REIT – Healthcare Facilities company that operates in wider Real Estate sector, reached to the highest price of $19.23 whereas the lowest price it dropped to was $18.69. The 52-week range on CHCT shows that it touched its highest point at $28.10 and its lowest point at $15.06 during that stretch. It currently has a 1-year price target of $21.20. With its current market cap of 542.26 million, CHCT has annualized dividend of $1.84 while the current yield stands at 9.61%. Beta for the stock currently stands at 0.67.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CHCT was down-trending over the past week, with a drop of -0.05%, but this was up by 5.84% over a month. Three-month performance surged to 16.22% while six-month performance fell -19.77%. The stock lost -25.73% in the past year, while it has lost -0.05% so far this year. A look at the trailing 12-month EPS for CHCT yields -0.11 with Next year EPS estimates of 0.37. For the next quarter, that number is 0.07. This implies an EPS growth rate of -160.00% for this year and 408.33% for next year. EPS is expected to grow by 4.30% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 1.34%.
Float and Shares Shorts:
At present, 28.24 million CHCT shares are outstanding with a float of 26.85 million shares on hand for trading. On 2024-12-13, short shares totaled 0.63 million, which was 222.00000000000003 higher than short shares on 1731628800. In addition to Mr. David H. Dupuy as the firm’s CEO, President, Secretary & Director, Mr. William G. Monroe IV serves as its Executive VP & CFO.
Institutional Ownership:
Through their ownership of 0.88862 of CHCT’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, CHCT reported revenue of $29639000.0 and operating income of $7791000.0. The EBITDA in the recently reported quarter was $19176000.0 and diluted EPS was $0.04.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CHCT since 2 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With CHCT analysts setting a high price target of 25.0 and a low target of 19.0, the average target price over the next 12 months is 21.2. Based on these targets, CHCT could surge 30.21% to reach the target high and fall by -1.04% to reach the target low. Reaching the average price target will result in a growth of 10.42% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.11456 being high and -$0.12504 being low. For CHCT, this leads to a yearly average estimate of -$0.12. Based on analyst estimates, the high estimate for the next quarter is $0.08 and the low estimate is $0.08. The average estimate for the next quarter is thus $0.08.
